Efkarpia

• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl … Recruiting
  2023-506891-28-00 5 2022-05-02 The target population of interest in this study is participants with l
• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Recruiting
  2023-508956-20-00 5 2020-03-12 Hidradenitis suppurativa
• A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou … Ended recruitment
  2025-522598-12-00 10 2025-12-17 Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part … Ended recruitment
  2023-506146-23-00 4 2025-11-17 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended recruitment
  2023-503539-16-00 5 2025-11-11 Non-small Cell Lung Cancer (NSCLC)
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening); … Ended recruitment
  2024-519000-27-00 5 2025-07-17 Hypertension
• A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended recruitment
  2024-516745-39-00 4 2025-07-11 Cutaneous lupus erythematosus
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• EMAPALUMAB TREATMENT FOR ANTICIPATED CLINICAL BENEFIT IN SEPSIS DRIVEN BY THE INTERFERON-GAMMA ENDOTYPE (THE EMBRACE TRIAL) Ended recruitment
  2024-515255-38-00 4 2025-03-12 SEPSIS
• AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protoco … Ended recruitment
  2024-511253-21-00 3 2025-02-28 Thoracic tumors with homozygous MTAP-deletion
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended recruitment
  2024-510753-10-00 5 2024-11-01 Prurigo Nodularis
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• Effects of the combination of two drugs called irbesartan and amlodipine, in one pill in patients with high blood pressure. Ended recruitment
  2024-511705-31-00 5 2024-09-26 Arterial Hypertension
• AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous … Ended recruitment
  2024-511195-33-00 3 2024-09-23 Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Patient Preference for Route of Administration with Intravenous Infusion Switch to Subcutaneous I-O Regimens in Melanoma Ended recruitment
  2023-504515-33-00 4 2024-02-19 Melanoma

Showing 49–72 of 118 trials